This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is (1) to test the efficacy of low-dose hydrocortisone therapy during the first two weeks of life for prevention of chronic lung disease at 36 weeks postmenstrual age; (2) to assess potential short- and long-term risks of this therapy, including evaluation of neurodevelopmental and somatic outcomes at 18-22 months adjusted age; (3) to evaluate the effects of low-dose hydrocortisone therapy on signs of possible adrenal insufficiency, specifically hypotension, hyponatremia, hyperkalemia, and feeding intolerance; (4) to elucidate the relationship of systemic concentrations of the cytokines interleukin 1B, interleukin 6 and interleukin 8 to prenatal factors (e.g., chorioamnionitis) and to clinical outcomes in this population and to investigate the effect of hydrocortisone therapy on these markers of systemic inflammation.
Showing the most recent 10 out of 568 publications
